TEVA

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: VTRS PRGO AMRX GSK BMY PFE MRK NVS ABBV JNJ

| Held by: IEFA EFA EIS EFV IXUS SPDW IDEV FNDF PPH WCMI

Scroll to Statements

Index	-	P/E	25.51	EPS (ttm)	1.22	Insider Own	0.02%	Shs Outstand	1.16B	Perf Week	-8.30%
Market Cap	36.16B	Forward P/E	10.03	EPS next Y	3.10	Insider Trans	-90.90%	Shs Float	1.16B	Perf Month	-11.18%
Enterprise Value	49.80B	PEG	1.81	EPS next Q	0.55	Inst Own	60.41%	Short Float	3.15%	Perf Quarter	11.57%
Income	1.42B	P/S	2.08	EPS this Y	-7.70%	Inst Trans	1.02%	Short Ratio	3.91	Perf Half Y	68.02%
Sales	17.39B	P/B	4.51	EPS next Y	14.51%	ROA	3.54%	Short Interest	36.64M	Perf YTD	-0.51%
Book/sh	6.88	P/C	10.17	EPS next 5Y	5.53%	ROE	21.37%	52W High	37.35 -16.86%	Perf Year	102.28%
Cash/sh	3.05	P/FCF	36.02	EPS past 3/5Y	- -	ROIC	6.12%	52W Low	12.47 149.10%	Perf 3Y	213.32%
Dividend Est.	-	EV/EBITDA	9.95	Sales past 3/5Y	5.53% 0.80%	Gross Margin	51.82%	Volatility	3.06% 2.65%	Perf 5Y	195.15%
Dividend TTM	-	EV/Sales	2.86	EPS Y/Y TTM	185.44%	Oper. Margin	22.96%	ATR (14)	1.07	Perf 10Y	-44.17%
Dividend Ex-Date	Nov 27, 2017	Quick Ratio	0.80	Sales Y/Y TTM	4.73%	Profit Margin	8.16%	RSI (14)	32.30	Recom	1.46
Dividend Gr. 3/5Y	- -	Current Ratio	1.04	EPS Q/Q	313.26%	SMA20	-7.82%	Beta	0.73	Target Price	39.78
Payout	0.00%	Debt/Eq	2.17	Sales Q/Q	12.42%	SMA50	-5.84%	Rel Volume	0.82	Prev Close	31.75
Employees	33346	LT Debt/Eq	1.93	Earnings	Jan 28 BMO	SMA200	33.78%	Avg Volume	9.38M	Price	31.05
IPO	Feb 16, 1982	Option/Short	Yes / Yes	EPS/Sales Surpr.	49.70% 9.13%	Trades		Volume	7,702,294	Change	-2.20%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$35
Dec-05-25	Initiated	Scotiabank	Sector Outperform	$35
Jun-06-25	Initiated	Goldman	Buy	$24
May-28-25	Initiated	Truist	Buy	$25
May-12-25	Upgrade	JP Morgan	Neutral → Overweight	$23
Jul-10-24	Upgrade	Argus	Hold → Buy	$20
Mar-08-24	Upgrade	JP Morgan	Underweight → Neutral	$14
Feb-12-24	Upgrade	Piper Sandler	Neutral → Overweight	$12 → $19
Jan-23-24	Upgrade	Jefferies	Hold → Buy	$10 → $14
Jan-03-24	Upgrade	Piper Sandler	Underweight → Neutral	$8 → $12
Dec-18-23	Initiated	HSBC Securities	Buy	$13
Nov-27-23	Upgrade	UBS	Neutral → Buy	$11 → $13
Jul-06-23	Upgrade	UBS	Sell → Neutral	$7 → $8
May-25-23	Initiated	Morgan Stanley	Equal-Weight	$10
May-18-23	Upgrade	Evercore ISI	In-line → Outperform
Jan-19-23	Downgrade	Jefferies	Buy → Hold	$10 → $12
Nov-14-22	Downgrade	JP Morgan	Neutral → Underweight	$11 → $10
Nov-04-22	Downgrade	UBS	Neutral → Sell
Oct-21-22	Resumed	Jefferies	Buy	$10
Aug-05-22	Upgrade	BofA Securities	Neutral → Buy	$10 → $13

Show Previous Ratings

Mar-06-26 07:44PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
Mar-05-26 08:29AM	Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead? (Zacks)
03:57AM	Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's (Zacks)
Mar-04-26 09:42AM	3 Generic Drug Stocks to Watch Despite Industry Headwinds (Zacks)
06:57AM	Blackstone puts $400M into Teva, Sanofi gut disease drug (BioPharma Dive)
05:00PM	Loading…
Mar-03-26 05:00PM	Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug (GlobeNewswire)
Mar-02-26 10:09AM	Israeli stocks rally after missile attacks on Iran (MarketWatch)
Feb-27-26 10:24AM	Amneal Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
10:02AM	J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold? (Zacks)
Feb-26-26 11:53PM	Where is Teva Pharmaceutical Industries Limited (TEVA) Headed? (Insider Monkey)
Feb-25-26 09:40AM	Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year? (Zacks)
09:12AM	Corcept's Q4 Earnings and Revenues Fall Short of Estimates (Zacks)
Feb-24-26 11:11PM	Corcept Therapeutics Q4 Earnings Call Highlights (MarketBeat)
04:30PM	Teva to Present at the Upcoming Investor Conferences in March (GlobeNewswire)
Feb-23-26 08:48AM	FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application (Benzinga)
06:57AM	Loading…
06:57AM	Are Wall Street Analysts Bullish on Deckers Outdoor Stock? (Barchart)
Feb-20-26 03:37PM	Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults (Business Wire)
02:43PM	U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults (GlobeNewswire)
12:00PM	Teva Pharmaceutical Industries (TEVA) Upgraded to Buy: Here's What You Should Know (Zacks)
03:44AM	Truist Boosts Teva (TEVA) Stock Target Amid Pipeline Growth Opportunities (Insider Monkey)
Feb-19-26 11:48AM	Corcept Therapeutics Stock Plunges As Court Clears Teva Generic (Benzinga)
Feb-18-26 09:00PM	Goldman Sachs See Teva Pharmaceutical Industries Limited (TEVA) Driving Double-Digit Earnings Growth Through 2026 (Insider Monkey)
05:35AM	FDA accepts BMS protein degrader for review; Disc rare disease drug rejected (BioPharma Dive)
Feb-17-26 12:56PM	Should You Invest in Teva Pharmaceutical (TEVA), Here's What the Street Has to Say (Insider Monkey)
07:04AM	Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients (Benzinga)
06:00AM	Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease (GlobeNewswire)
Feb-10-26 06:41AM	Here's What Analysts Are Saying About Teva Pharmaceutical (TEVA) Post Earnings (Insider Monkey)
Feb-04-26 09:05AM	Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat (Insider Monkey)
Feb-03-26 09:34PM	Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory (Insider Monkey)
Feb-02-26 01:30AM	The Druckenmiller Connection: Meet the Man Behind Bessent and Warsh (Barrons.com)
09:35AM	Loading…
Jan-31-26 09:35AM	Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds (Insider Monkey)
08:48AM	Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis (Insider Monkey)
Jan-30-26 10:08AM	Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic (Benzinga)
Jan-29-26 12:36PM	Novo Nordisk Faces Class Action Over Victoza Generic Delay (GuruFocus.com)
11:23AM	TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth (Zacks)
10:05AM	What Makes Teva Pharmaceuticals (TEVA) a Successful Brand? (Insider Monkey)
12:06AM	Teva Pharmaceutical Industries Q4 Earnings Call Highlights (MarketBeat)
Jan-28-26 04:26PM	Teva CEO Explains 'Remarkable Story' Behind Guidance (Investor's Business Daily)
03:25PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
01:01PM	Gold Rallies To $5,300, Memory Stocks Go Wild: What's Moving Markets Wednesday? (Benzinga)
12:22PM	Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook (Benzinga)
11:10AM	Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance? (Zacks)
10:02AM	Teva Pharma Slides On 2026 Guidance Surprise Despite Fourth-Quarter Beat (Investor's Business Daily)
09:40AM	Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock (Zacks)
09:30AM	Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:46AM	Teva Pharma Slides On Light 2026 Outlook Despite Fourth-Quarter Beat (Investor's Business Daily)
07:00AM	Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential (GlobeNewswire)
Jan-27-26 10:51AM	J&J Targets $100B+ Sales in 2026 as Growth Accelerates in Both Units (Zacks)
08:00AM	Will Forte Teams Up with Teva to Get Real About Huntington's Disease with 'Honestly HD' (GlobeNewswire)
Jan-23-26 09:15AM	What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q4 Earnings (Zacks)
Jan-21-26 12:14PM	Dr. Reddy's Laboratories Q3 Earnings Call Highlights (MarketBeat)
10:28AM	J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive Sales (Zacks)
Jan-19-26 09:07AM	Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results? (Zacks)
Jan-16-26 08:53AM	JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency (Pharmaceutical Technology)
08:52AM	ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now? (Zacks)
Jan-15-26 09:50AM	Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
Jan-14-26 05:02PM	AJOVY (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine (GlobeNewswire)
Jan-13-26 09:04PM	Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025 (MarketBeat)
04:48PM	Teva's Plans to Pivot to Growth (Bloomberg)
11:16AM	Judge Denies Teva Bid To Pause Paragard Copper Contraceptive Device Lawsuit Trial (Benzinga)
Jan-12-26 12:26PM	Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug (Benzinga)
10:46AM	Teva Stock Is Jumping. Why Investors Are So Optimistic on the Drugmaker. (Barrons.com)
10:08AM	TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug (Zacks)
09:40AM	Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term (Zacks)
Jan-11-26 06:00PM	Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation (GlobeNewswire)
05:00PM	Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo (GlobeNewswire)
Jan-10-26 02:57PM	Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32 (Insider Monkey)
Jan-06-26 11:44AM	ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now? (Zacks)
11:15AM	Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings? (Zacks)
Jan-05-26 04:30PM	Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
09:07AM	Should You Buy the Dip in This S&P 500 Underdog in 2026? (Barchart)
Dec-30-25 07:40AM	Here's What to Expect From Deckers Outdoor's Next Earnings Report (Barchart)
Dec-29-25 11:59PM	What Do Analysts Think About Teva Pharmaceutical Industries (TEVA)? (Insider Monkey)
Dec-26-25 10:45AM	This International Pharma Stock Just Hit 5-Year Highs (Barchart)
Dec-24-25 08:36AM	S&P Global Ratings Upgrades Teva to 'BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive (GlobeNewswire)
04:11AM	Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 (Motley Fool)
Dec-22-25 11:21AM	J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play (Zacks)
Dec-19-25 03:40AM	Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea (GlobeNewswire)
03:26AM	My Top 10 Portfolio Holdings for 2026 (Motley Fool)
Dec-18-25 09:40AM	Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock (Zacks)
Dec-17-25 05:09PM	BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight (Insider Monkey)
02:53PM	3 Things You Need to Know if You Buy Teva Pharmaceutical Stock Today (Motley Fool)
07:44AM	S&P 500 Stocks: These 2 Lagging Retailers Become Leaders In December (Investor's Business Daily)
Dec-16-25 10:30AM	FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? (Zacks)
Dec-14-25 03:47PM	Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? (Motley Fool)
Dec-12-25 04:30PM	Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 (GlobeNewswire)
04:30PM	Teva Releases Q4 2025 Aide Memoire (GlobeNewswire)
Dec-11-25 08:26PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
10:11AM	Crypto Market 2026 Predictions: Which Coins Will 10x and Which Will Crash? (24/7 Wall St.)
10:11AM	Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks (24/7 Wall St.)
Dec-10-25 09:24PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
09:43AM	TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia (Zacks)
Dec-09-25 11:12AM	Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play (Zacks)
08:00AM	Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults (GlobeNewswire)
04:53AM	Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's (Zacks)
Dec-08-25 11:10AM	Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026? (Zacks)
08:23AM	3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape (Zacks)
03:34AM	Is Deckers Outdoor Stock Underperforming the S&P 500? (Barchart)
Dec-06-25 09:52AM	Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue (24/7 Wall St.)
Dec-05-25 09:57AM	Can Galafold Continue to Drive Amicus' Top Line in 2026? (Zacks)

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Francis Richard D	President and CEO	Mar 04 '26	Sale	32.46	23,393	759,442	1,148,212	Mar 06 04:19 PM
Daniell Richard	EVP, Europe Commercial	Mar 04 '26	Sale	32.66	91,345	2,983,517	85,755	Mar 06 04:17 PM
Hughes Eric A	See "Remarks"	Mar 04 '26	Sale	32.46	11,277	366,102	97,590	Mar 06 04:09 PM
Fox Christine	EVP, U.S. Commercial	Mar 04 '26	Sale	32.46	9,098	295,362	75,010	Mar 06 04:05 PM
Savage Brian	Interim Chief Legal Officer	Mar 04 '26	Sale	32.46	2,675	86,843	6,181	Mar 06 04:03 PM
Shields Matthew	Officer	Mar 05 '26	Proposed Sale	31.67	17,295	547,705		Mar 05 05:49 PM
Jover Placid	Officer	Mar 05 '26	Proposed Sale	31.67	14,150	448,108		Mar 05 05:43 PM
Savage Brian	Officer	Mar 05 '26	Proposed Sale	31.67	1,127	35,690		Mar 05 05:39 PM
Fox Christine	Officer	Mar 05 '26	Proposed Sale	31.67	7,924	250,940		Mar 05 05:32 PM
Francis Richard D	Officer	Mar 05 '26	Proposed Sale	31.67	20,025	634,160		Mar 05 05:26 PM
Hughes Eric A	Officer	Mar 05 '26	Proposed Sale	31.67	9,533	301,895		Mar 05 05:13 PM
Daniell Richard	Officer	Mar 05 '26	Proposed Sale	31.67	17,295	547,705		Mar 05 05:08 PM
Daniell Richard	EVP, Europe Commercial	Mar 03 '26	Sale	32.36	128,985	4,173,942	48,384	Mar 05 04:09 PM
Savage Brian	Interim Chief Legal Officer	Mar 03 '26	Sale	32.36	1,274	41,227	2,926	Mar 05 04:06 PM
Francis Richard D	President and CEO	Mar 03 '26	Sale	32.36	442,935	14,333,332	642,099	Mar 05 04:05 PM
Hughes Eric A	See "Remarks"	Mar 03 '26	Sale	32.36	80,762	2,613,450	12,823	Mar 05 04:01 PM
Fox Christine	Officer	Mar 04 '26	Proposed Sale	32.46	9,908	321,658		Mar 04 05:42 PM
Francis Richard D	Officer	Mar 04 '26	Proposed Sale	32.46	23,393	759,442		Mar 04 05:36 PM
Hughes Eric A	Officer	Mar 04 '26	Proposed Sale	32.46	11,277	366,102		Mar 04 05:28 PM
Daniell Richard	Officer	Mar 04 '26	Proposed Sale	32.66	91,345	2,983,516		Mar 04 05:22 PM
Savage Brian	Officer	Mar 03 '26	Proposed Sale	32.36	1,274	41,227		Mar 03 05:46 PM
Francis Richard D	Officer	Mar 03 '26	Proposed Sale	32.36	442,935	14,333,332		Mar 03 05:34 PM
Hughes Eric A	Officer	Mar 03 '26	Proposed Sale	32.36	80,762	2,613,450		Mar 03 05:25 PM
Daniell Richard	Officer	Mar 03 '26	Proposed Sale	32.36	128,985	4,173,942		Mar 03 05:13 PM
Kalif Eliyahu Sharon	EVP, Chief Financial Officer	Feb 26 '26	Sale	33.64	345,810	11,634,708	57,478	Mar 02 04:01 PM
Kalif Eliyahu Sharon	Officer	Feb 26 '26	Proposed Sale	33.64	345,810	11,634,702		Feb 26 04:11 PM
Francis Richard D	President and CEO	Feb 15 '26	Sale	34.22	447,778	15,324,799	271,783	Feb 18 04:01 PM
Francis Richard D	Officer	Feb 17 '26	Proposed Sale	1.00	447,778	447,778		Feb 18 06:12 AM
Weiss Amir	Chief Accounting Officer	Dec 16 '25	Sale	30.20	12,300	371,504	5,650	Dec 18 04:04 PM
MIGNONE ROBERTO	Director	Dec 16 '25	Sale	30.24	77,400	2,340,646	367,600	Dec 18 04:02 PM
Bridger Management, LLC (1)	Shareholder	Dec 12 '25	Proposed Sale	30.18	150,000	4,527,000		Dec 12 04:17 PM
Daniell Richard	Exec. VP, European Commercial	Dec 09 '25	Option Exercise	18.40	115,468	2,124,542	163,852	Dec 11 04:09 PM
Daniell Richard	Exec. VP, European Commercial	Dec 09 '25	Sale	28.68	115,468	3,311,126	48,384	Dec 11 04:09 PM
Sabag Mark	See "Remarks"	Dec 09 '25	Option Exercise	18.61	118,724	2,209,454	269,720	Dec 11 04:06 PM
Sabag Mark	See "Remarks"	Dec 09 '25	Sale	28.73	216,892	6,230,754	52,828	Dec 11 04:06 PM
Sabag Mark	Officer	Dec 09 '25	Proposed Sale	28.73	216,892	6,230,750		Dec 09 04:03 PM
Daniell Richard	Officer	Dec 09 '25	Proposed Sale	28.68	115,468	3,311,131		Dec 09 04:00 PM
MIGNONE ROBERTO	Director	Nov 26 '25	Sale	26.03	50,000	1,301,505	445,000	Dec 01 04:02 PM
Bridger Management, LLC (1)	Shareholder	Nov 26 '25	Proposed Sale	24.99	50,000	1,249,500		Nov 26 04:02 PM
Fox Christine	EVP, Head of U.S. Commercial	Nov 20 '25	Sale	24.78	28,229	699,523	63,647	Nov 24 04:03 PM
Fox Christine	Officer	Nov 20 '25	Proposed Sale	24.78	28,229	699,523		Nov 20 04:19 PM
Fox Christine	EVP, Head of U.S. Commercial	Nov 14 '25	Sale	25.11	30,000	753,321	28,384	Nov 18 04:01 PM
Fox Christine	Officer	Nov 14 '25	Proposed Sale	25.11	30,000	753,321		Nov 14 03:59 PM
MIGNONE ROBERTO	Director	Nov 06 '25	Sale	24.11	200,000	4,821,880	495,000	Nov 10 04:15 PM
Weiss Amir	Chief Accounting Officer	Nov 06 '25	Sale	24.44	12,300	300,564	17,950	Nov 10 04:06 PM
Bridger Management, LLC (1)	Shareholder	Sep 12 '25	Proposed Sale	19.89	95,000	1,889,550		Sep 12 04:05 PM
McAvoy David R.	EVP, Chief Legal Officer	Sep 05 '25	Buy	18.86	1,113	20,988	13,027	Sep 09 04:02 PM
Jover Placid	See "Remarks"	Aug 01 '25	Sale	15.16	6,053	91,748	6,774	Aug 05 04:04 PM
Hughes Eric A	See "Remarks"	Aug 01 '25	Sale	15.16	52,742	799,437	0	Aug 05 04:02 PM
Jover Placid	Officer	Aug 01 '25	Proposed Sale	15.16	6,053	91,748		Aug 01 04:04 PM
Hughes Eric A	Officer	Aug 01 '25	Proposed Sale	15.16	52,742	799,437		Aug 01 04:01 PM
Kalif Eliyahu Sharon	EVP, Chief Financial Officer	Jun 12 '25	Sale	17.08	55,775	952,464	403,288	Jun 16 04:03 PM
Kalif Eliyahu Sharon	Officer	Jun 12 '25	Proposed Sale	17.08	55,775	952,466		Jun 12 04:18 PM
Shields Matthew	EVP, Global Operations	Jun 03 '25	Sale	17.02	6,206	105,628	9,989	Jun 05 05:08 PM
Shields Matthew	Officer	Jun 03 '25	Proposed Sale	17.02	6,206	105,628		Jun 03 03:59 PM
Sabag Mark	See "Remarks"	May 08 '25	Sale	18.04	337,915	6,097,304	150,996	May 12 04:00 PM
Sabag Mark	Officer	May 08 '25	Proposed Sale	18.04	337,915	6,097,324		May 08 02:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Teva- Pharmaceutical Industries Ltd. ADR

Upgrade your FINVIZ experience